Authorized purpose: Analyzes neurological MR images for automated segmentation, volumetric quantification, reporting, fusion, and longitudinal comparison of known pathologically confirmed brain tumors.
Clinical role
Fully automated post-processing of neurological MR image data that segments and volumetrically quantifies known, pathologically confirmed brain tumors, providing quantitative reports and derived image data as complementary information in the review of a case.
Keep in mind: Adults with known or confirmed pathologically diagnosed brain cancer; output is complementary information and the physician retains final diagnosis and treatment responsibility.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Analyzes neurological MR images for automated segmentation, volumetric quantification, reporting, fusion, and longitudinal comparison of known pathologically confirmed brain tumors.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain; pathologically confirmed brain tumors Input: DICOM neurological MR images, including DWI, from MRI or PACS workflows for adult patients with confirmed brain tumors.
Who uses it?Intended users: Radiologists, oncologists, and other trained clinicians or personnel.
What does the software produce?Output: Numerical volumes, grayscale maps, graphical color overlays, DICOM image series and reports, automated segmentation, quantification, fusion, and longitudinal comparisons.
What is its most important limitation?Key limitation: Adults with known or confirmed pathologically diagnosed brain cancer; output is complementary information and the physician retains final diagnosis and treatment responsibility.
Clinical takeaway. Clinical role: Analyzes neurological MR images for automated segmentation, volumetric quantification, reporting, fusion, and longitudinal comparison of known pathologically confirmed brain tumors.
Evidence takeaway. Evidence from the reviewed source record: FDA-reported software verification and validation, independent-test-set segmentation comparison against expert labels, and separate DWI unit, system, and clinical validation; no numeric claim is promoted.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Analyzes neurological MR images for automated segmentation, volumetric quantification, reporting, fusion, and longitudinal comparison of known pathologically confirmed brain tumors.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Fully automated post-processing of neurological MR image data that segments and volumetrically quantifies known, pathologically confirmed brain tumors, providing quantitative reports and derived image data as complementary information in the review of a case.
Exact FDA submission
Checked 2026-11-14
Packet wording: "OnQ Neuro is a fully automated post-processing medical device software intended for analyzing and evaluating neurological MR image data." … "performs 1) automatic segmentation and volumetric quantification of brain tumors, which are known/confirmed to be pathologically diagnosed cancer". Read from the exact FDA decision document on 2026-11-14.
Numerical volumes, grayscale maps, graphical color overlays, DICOM image series and reports, automated segmentation, quantification, fusion, and longitudinal comparisons.
Adults with known or confirmed pathologically diagnosed brain cancer; output is complementary information and the physician retains final diagnosis and treatment responsibility.
FDA-reported software verification and validation, independent-test-set segmentation comparison against expert labels, and separate DWI unit, system, and clinical validation; no numeric claim is promoted.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA-reported software verification and validation, independent-test-set segmentation comparison against expert labels, and separate DWI unit, system, and clinical validation; no numeric claim is promoted.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
OnQ Neuro regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested version1.2
IndependenceIndependence not established
K210831
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K210831. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM neurological MR images, including DWI, from MRI or PACS workflows for adult patients with confirmed brain tumors.
Scope: Exact FDA submission. FDA packet input and population scope.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes OnQ Neuro processing images sent from the MRI scanner or PACS, configured to receive input DICOM files from a network location and output DICOM to a network destination, with DICOM image series and reports displayable on most third-party commercial DICOM workstations. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "the OnQ Neuro software automatically processes images sent from the originating system (MRI scanner or PACS)." … "The software is configured at installation to receive input DICOM files from a network location, and output DICOM to a network destination.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes OnQ Neuro as a stand-alone software package designed to be installed in the cloud or within a hospital's IT infrastructure on a server or PC-based workstation. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The OnQ Neuro is a stand-alone medical device software package that is designed to be installed in the cloud or within a hospital’s IT infrastructure on a server or PC-based workstation.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Numerical volumes, grayscale maps, graphical color overlays, DICOM image series and reports, automated segmentation, quantification, fusion, and longitudinal comparisons.
Scope: Exact FDA submission. FDA packet output scope.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Numerical volumes, grayscale maps, graphical color overlays, DICOM image series and reports, automated segmentation, quantification, fusion, and longitudinal comparisons.
Scope: Exact FDA submission. FDA packet output scope.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes OnQ Neuro as a stand-alone software package designed to be installed in the cloud or within a hospital's IT infrastructure on a server or PC-based workstation. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The OnQ Neuro is a stand-alone medical device software package that is designed to be installed in the cloud or within a hospital’s IT infrastructure on a server or PC-based workstation.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes OnQ Neuro processing images sent from the MRI scanner or PACS, configured to receive input DICOM files from a network location and output DICOM to a network destination, with DICOM image series and reports displayable on most third-party commercial DICOM workstations. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "the OnQ Neuro software automatically processes images sent from the originating system (MRI scanner or PACS)." … "The software is configured at installation to receive input DICOM files from a network location, and output DICOM to a network destination.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K210831 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: LiverMultiScan v6.0 is MR diagnostic software for non-invasive liver-health assessment that generates, displays, and supports review of MR data and quantitative cT1, PDFF, and LIC metrics or composite images for trained healthcare-professional interpretation.
Authorized purpose: TumorSight Viz processes dynamic contrast-enhanced breast MRI for patients with biopsy-proven early-stage or locally advanced breast cancer, providing registration, subtraction, segmentation, 3D renderings, measurements, kinetic curves, parametric maps, MIPs, and reformats for physician visualization and analysis; results are not the sole basis for patient management.
Authorized purpose: Prenuvo Body Composition is software that non-invasively quantifies fat, muscle, and organs from compatible MR DICOM datasets and displays internal body information, including liver and body-composition measurements, for adults age 18 and older.
Modality
MRI
Anatomy
Whole-body anatomy, liver, organs, fat, and muscle
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.